ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,728,957 | +11.3% | 2,421,743 | -0.1% | 1.88% | -2.2% |
| Q2 2023 | $24,918,319 | +39.3% | 2,423,961 | +4.6% | 1.92% | +13.5% |
| Q1 2023 | $17,892,134 | +5.0% | 2,317,634 | 0.0% | 1.70% | -15.2% |
| Q4 2022 | $17,034,610 | +6.8% | 2,317,634 | +4.6% | 2.00% | -5.9% |
| Q3 2022 | $15,946,000 | +126.6% | 2,214,722 | +167.9% | 2.13% | +51.5% |
| Q2 2022 | $7,036,000 | +133.3% | 826,779 | +145.9% | 1.40% | +75.8% |
| Q1 2022 | $3,016,000 | – | 336,229 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |